Oncostatin-M ligand-based CAR-T therapy displays robust anti-tumor activity against osteosarcoma.

Saved in:
Bibliographic Details
Title: Oncostatin-M ligand-based CAR-T therapy displays robust anti-tumor activity against osteosarcoma.
Authors: Feinberg D; Department of Pathology, Case Western Reserve University, Cleveland, OH, USA., Uppin V; Department of Medicine, Division of Hematology/Oncology, Case Western Reserve University, Cleveland, OH, USA., Eid S; Department of Pediatrics, Case Western Reserve University School of Medicine, Cleveland, OH, USA., Fritz C; Department of Pathology, Case Western Reserve University, Cleveland, OH, USA., Hitomi M; Department of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH, USA.; Department of Molecular Medicine, The Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA., Radhakrishnan A; Department of Medicine, Division of Hematology/Oncology, Case Western Reserve University, Cleveland, OH, USA., Klatt K; Department of Pathology, Case Western Reserve University, Cleveland, OH, USA., Choi SH; Department of Pediatrics, Case Western Reserve University School of Medicine, Cleveland, OH, USA.; Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA., Myers JT; Department of Pediatrics, Case Western Reserve University School of Medicine, Cleveland, OH, USA., Bhatt A; Department of Medicine, Division of Hematology/Oncology, Case Western Reserve University, Cleveland, OH, USA., Stearns D; Department of Pediatrics, Case Western Reserve University School of Medicine, Cleveland, OH, USA.; Division of Pediatrics-Hematology and Oncology, UH Rainbow Babies and Children's Hospital, Cleveland, OH, USA., Pateva I; Department of Pediatrics, Case Western Reserve University School of Medicine, Cleveland, OH, USA.; Division of Pediatrics-Hematology and Oncology, UH Rainbow Babies and Children's Hospital, Cleveland, OH, USA., Burke ZDC; Department of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH, USA.; Department of Orthopedic Surgery, Cleveland Clinic, Cleveland, OH, USA., Huang AY; Department of Pathology, Case Western Reserve University, Cleveland, OH, USA.; Department of Pediatrics, Case Western Reserve University School of Medicine, Cleveland, OH, USA.; Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA.; Division of Pediatrics-Hematology and Oncology, UH Rainbow Babies and Children's Hospital, Cleveland, OH, USA.; Center for Pediatric Immunotherapy, Angie Fowler AYA Cancer Institute, UH Rainbow Babies & Children's Hospital, Cleveland, OH, USA., Schwartz GK; Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA., Parameswaran R; Department of Pathology, Case Western Reserve University, Cleveland, OH, USA. rxp278@case.edu.; Department of Medicine, Division of Hematology/Oncology, Case Western Reserve University, Cleveland, OH, USA. rxp278@case.edu.; Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA. rxp278@case.edu.; Division of Pediatrics-Hematology and Oncology, UH Rainbow Babies and Children's Hospital, Cleveland, OH, USA. rxp278@case.edu.
Source: BMC medicine [BMC Med] 2026 Mar 17; Vol. 24 (1). Date of Electronic Publication: 2026 Mar 17.
Publication Type: Journal Article
Journal Info: Publisher: BioMed Central Country of Publication: England NLM ID: 101190723 Publication Model: Electronic Cited Medium: Internet ISSN: 1741-7015 (Electronic) Linking ISSN: 17417015 NLM ISO Abbreviation: BMC Med Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1741-7015
DOI:10.1186/s12916-026-04729-8